Adiponectin, the hormone that protects women against liver cancer

(Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)) The study, published in the Journal of Experimental Medicine, shows that adiponectin protects the liver against the development of the main form of liver cancer, hepatocellular carcinoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 19 June 2019Source: Chemico-Biological InteractionsAuthor(s): Yeonhwa Song, I-Seul Park, Jiho Kim, Inhee Choi, Haeng Ran SeoAbstractLiver cancer is one of the most frequently occurring types of cancer with high mortality rate. Hepatocellular carcinoma (HCC) frequently metastasizes to lung, portal vein, and portal lymph nodes and most HCCs show strong resistance to conventional anticancer drugs. Cancer stem cells (CSCs) are considered to be responsible for resistance to therapies. Hence, recent advancements in the use of liver cancer stem cells (LCSCs) are rapidly gaining recognition as an...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Publication date: Available online 19 June 2019Source: Genes &DiseasesAuthor(s): Wei Wang, Bo Hu, Jiang-Jiang Qin, Jianwen Cheng, Xin Li, Mehrdad Rajaei, Jia Fan, Xin-Rong Yang, Ruiwen ZhangAbstractOverexpression of the MDM2 oncogene and mutations in the p53 tumor suppressor commonly occur in hepatocellular carcinoma (HCC) and are associated with increased mortality due to this disease. Inhibiting MDM2 has been demonstrated to be a valid approach for the treatment of HCC. However, most of the MDM2 inhibitors evaluated to date have been designed to block the MDM2 and p53 binding, and have limited efficacy against tumors...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
SHANGHAI, June 19, 2019 -- (Healthcare Sales &Marketing Network) -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT0... Biopharmaceuticals, Oncology, FDA CARsgen Therapeutics, T cell, CAR-T, hepatocellular carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
unil Sharma Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide, with a majority of HCC patients not suitable for curative therapies. Approximately 70% of initially diagnosed patients cannot undergo surgical resection or transplantation candidates due to locally advanced disease, poor liver function/underlying cirrhosis, or additional comorbidities. Local therapeutic options for patients with unresectable HCC, not suitable for thermal ablation, include transarterial embolization (bland, chemoembolization, radioembolization) and/or external beam radiation therapy (EBRT). Regarding EBRT specifically,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we explored the biological functions of FTCD in HCC. MATERIAL AND METHODS The expression and clinical correlation of FTCD in HCC tissue were analyzed using TCGA (The Cancer Genome Atlas) and a cohort of 60 HCC patients. The MEXPRESS platform was accessed to identify the methylation level in promoter region FTCD. CCK-8 assay and flow cytometry analysis were used to explore the proliferation, cell apoptosis proportion, and DNA damage in HCC cells with FTCD overexpression. Western blot analysis was performed to identify the downstream target of FTCD. RESULTS FTCD is significantly downregulated in HCC tissues an...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
(SAGE) Poor oral health is associated with a 75% increased risk of hepatocellular carcinoma (HCC), the most common form of liver cancer, new research published in UEG Journal has found.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the ...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
ConclusionsTriple ‐drug TACE seems to benefit patients with HCC larger than 10 cm in particular compared with single‐drug TACE.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusions: Mipsagargin is relatively well tolerated and promotes prolonged disease stabilization in patients with advanced HCC that had progressed on prior treatment with sorafenib. A significant decrease in Ktrans upon treatment suggests mipsagargin reduces blood flow in hepatic lesions.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Heart | Hepatocellular Carcinoma | Hormones | Liver | Liver Cancer | Study | Urology & Nephrology | Women